Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 209.02

+3.2%

Nov 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jayhawk969 who wrote (22911)	7/4/1998 2:05:00 PM
From: J Stone	Read Replies (1) of 32384

<Ontack is not yet approved and failure to aprove will provide a hit to this stock.> In your own words: <I believe investors are responding negatively to this threat and the delay of Ontak.> This indicates the stock has already been hit. The probability of Ontak not being approved is minute given the full panel recommendation. The Karposi's decline is not such a big issue. Panretin's approval for Karposi's will allow for larger off-label usages. Also, Panretin has proved to be significantly <effective in human trials.> And I believe Henry can state that Targretin has also proven to be quite effective. The approval of Ontak alone should give LGND's stock a small boost for psychological reasons, since most Biotechs never get any drugs approved. Coupled with an approval for Panretin the stock will do even better. From a short-term risk/reward perspective, I agree the SRGN play is probably the best opportunity. FWIW Jeff

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next